Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab
Addition of durvalumab to azacitidine did not improve ORR or OS among older patients with newly diagnosed AML and HR-MDS independent of SF mutation status.<b>Trial registration:</b> NCT02775903.
Authors
- Brian A. Fox (ORCID: https://orcid.org/0000-0001-6620-3853)
- Maximilian Stahl (ORCID: https://orcid.org/0000-0002-1299-5901)
- Nikolai Alexandrovich Podoltsev (ORCID: https://orcid.org/0000-0002-3657-778X)
- Daniel L. Menezes
- Tariq Zuheir Kewan (ORCID: https://orcid.org/0000-0003-4651-5125)
- Torsten Haferlach (ORCID: https://orcid.org/0000-0003-0196-2837)
- Ethan Thompson
- Stephanie Halene (ORCID: https://orcid.org/0000-0002-2737-9810)
- Amer Methqal Zeidan (ORCID: https://orcid.org/0000-0001-7017-8160)
- Isaac W. Boss
- Vanessa Hasle (ORCID: https://orcid.org/0000-0001-8007-4891)
- Lourdes Mendez (ORCID: https://orcid.org/0000-0002-5922-2877)
- Jan Philipp Bewersdorf (ORCID: https://orcid.org/0000-0003-3352-0902)
- Rory Michael Shallis (ORCID: https://orcid.org/0000-0002-8542-2944)
- Shelonitda Rose
Institutions
- Harvard University (US)
- Yale University (US)
- Bristol-Myers Squibb (United States) (US)
- Munich Leukemia Laboratory (Germany) (DE)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- Therapeutic Advances in Hematology
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1177/20406207251347344
- Citations
- 1
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Leukemia and Lymphoma Society
- National Cancer Institute